Abbott's reaffirmation of its FY23 adjusted EPS guidance, which is in line with the consensus estimate, indicates that the company's financial outlook is stable. This could maintain investor confidence in the company, but it's unlikely to significantly move the stock price in the short term as it doesn't represent new or unexpected information.